Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Lutio has the potential to offer significant cost savings when available to UK patients.
Subscribe To Our Newsletter & Stay Updated
